Loading stock data…
NNVC
$1.40-0.03 (-2.10%)
After Hours$1.36-0.04 (-2.83%)· Last close Jun 9
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NanoViricides, Inc. in the Healthcare sector is trading at $1.40. Wall Street consensus targets $6.00 (1 analysts), implying a +328.6% move over the next 12 months. The stock is currently 37% below its 52-week high of $2.23, remaining 8.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +328.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.40
Potential Downside
0%
Whystock Fair Value$1.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-88.39%
Volume
Today's trading volume
278,193
Recent News
NanoViricides closes $2M direct offering
NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in...
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak
NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health Organisation to declare a global health emergency. The WHO designated the outbreak in...
NanoViricides to raise $2M in registered direct offering
NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering. Under the terms of the agreement, the company will sell just over 1.3 million common...
Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs
By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets into the lungs through droplets of cough or spit from an infected person and incidents are becoming more common on cruises, making a global […]
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak
NanoViricides (NYSE-A:NNVC) is pointing to its lead drug candidate NV-387 as a potential solution to a critical gap in infectious disease preparedness, as a deadly hantavirus outbreak aboard a cruise ship triggers a costly global containment effort. The Connecticut-based clinical-stage...